Testicular cancer historical perspective: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (8 intermediate revisions by 2 users not shown) | |||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
There is a limited information about the historical perspective of [[testicular]] [[germ cell tumors]]. [[Leydig cells]] were first discovered by Franz Leydig who was a German [[anatomist]] in 1870. | |||
==Historical Perspective== | ==Historical Perspective== | ||
===Discovery=== | ===Discovery=== | ||
* There is limited information about the historical perspective of [ | * There is a limited information about the historical perspective of [[Testicular tumor|testicular tumors]]. [[Leydig cells]] were first discovered by Franz Leydig who was a German [[anatomist]] in 1870.<ref name="pmid17284120">{{cite journal |vauthors=Al-Agha OM, Axiotis CA |title=An in-depth look at Leydig cell tumor of the testis |journal=Arch. Pathol. Lab. Med. |volume=131 |issue=2 |pages=311–7 |date=February 2007 |pmid=17284120 |doi=10.1043/1543-2165(2007)131[311:AILALC]2.0.CO;2 |url=}}</ref> | ||
===Landmark Events in the Development of Treatment Strategies=== | ===Landmark Events in the Development of Treatment Strategies=== | ||
*In 1965, Dr. Barnett Rosenberg, a [[biophysics]] [[research]] at Michigan State University, discovered [[cisplatin]] [[drug]] which affects the [[cells]] [[Division (biology)|division]]. The blockage of [[cell]] division was from the [[platinum]] found in the [[electrodes]]. The [[experiment]] was tested in the mice at low [[dose]] of [[cisplatin]] since [[cisplatin]] at high [[doses]] might cause [[renal]] [[Toxicity|toxicities]].<ref name="urlDiscovery – Cisplatin and The Treatment of Testicular and Other Cancers - National Cancer Institute">{{cite web |url=https://www.cancer.gov/research/progress/discovery/cisplatin |title=Discovery – Cisplatin and The Treatment of Testicular and Other Cancers - National Cancer Institute, The "Accidental" Cure—Platinum-based Treatment for Cancer: The Discovery of Cisplatin|format= |work= |accessdate=}}</ref><ref name="pmid20377835">{{cite journal |vauthors=Nakamura T, Miki T |title=Recent strategy for the management of advanced testicular cancer |journal=Int. J. Urol. |volume=17 |issue=2 |pages=148–57 |date=February 2010 |pmid=20377835 |doi=10.1111/j.1442-2042.2009.02431.x |url=}}</ref> | |||
=== | *In 1972, National Cancer Institute stepped in and participated in the funding of the [[clinical trials]] in human [[Patient|patients]] with advanced [[testicular]] [[cancers]] under the supervision of Dr. lawrence Einhorn at Indiana University. | ||
*In 1978, [[Food and Drug Administration|Food and Drugs Administration]] (FDA) approved [[cisplatin]] [[drug]] for the treatment of testicular cancer based on successful [[clinical trials]]. [[Cisplatin]] has improved the lives of many [[patients]] diagnosed with [[Testicular cancer|testicular cancers]] and others when combining with others [[drugs]].<ref name="pmid22844263">{{cite journal |vauthors=Gómez-Ruiz S, Maksimović-Ivanić D, Mijatović S, Kaluđerović GN |title=On the discovery, biological effects, and use of Cisplatin and metallocenes in anticancer chemotherapy |journal=Bioinorg Chem Appl |volume=2012 |issue= |pages=140284 |date=2012 |pmid=22844263 |pmc=3401524 |doi=10.1155/2012/140284 |url=}}</ref> | |||
=== | |||
==References== | ==References== | ||
| Line 28: | Line 21: | ||
{{WS}} | {{WS}} | ||
[[Category: (name of the system)]] | [[Category: (name of the system)]] | ||
[[Category:Disease]] | [[Category:Disease]] | ||
Latest revision as of 09:52, 24 May 2019
|
Testicular cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Testicular cancer historical perspective On the Web |
|
American Roentgen Ray Society Images of Testicular cancer historical perspective |
|
Risk calculators and risk factors for Testicular cancer historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Gertrude Djouka, M.D.[2]
Overview
There is a limited information about the historical perspective of testicular germ cell tumors. Leydig cells were first discovered by Franz Leydig who was a German anatomist in 1870.
Historical Perspective
Discovery
- There is a limited information about the historical perspective of testicular tumors. Leydig cells were first discovered by Franz Leydig who was a German anatomist in 1870.[1]
Landmark Events in the Development of Treatment Strategies
- In 1965, Dr. Barnett Rosenberg, a biophysics research at Michigan State University, discovered cisplatin drug which affects the cells division. The blockage of cell division was from the platinum found in the electrodes. The experiment was tested in the mice at low dose of cisplatin since cisplatin at high doses might cause renal toxicities.[2][3]
- In 1972, National Cancer Institute stepped in and participated in the funding of the clinical trials in human patients with advanced testicular cancers under the supervision of Dr. lawrence Einhorn at Indiana University.
- In 1978, Food and Drugs Administration (FDA) approved cisplatin drug for the treatment of testicular cancer based on successful clinical trials. Cisplatin has improved the lives of many patients diagnosed with testicular cancers and others when combining with others drugs.[4]
References
- ↑ Al-Agha OM, Axiotis CA (February 2007). "An in-depth look at Leydig cell tumor of the testis". Arch. Pathol. Lab. Med. 131 (2): 311–7. doi:10.1043/1543-2165(2007)131[311:AILALC]2.0.CO;2. PMID 17284120.
- ↑ "Discovery – Cisplatin and The Treatment of Testicular and Other Cancers - National Cancer Institute, The "Accidental" Cure—Platinum-based Treatment for Cancer: The Discovery of Cisplatin".
- ↑ Nakamura T, Miki T (February 2010). "Recent strategy for the management of advanced testicular cancer". Int. J. Urol. 17 (2): 148–57. doi:10.1111/j.1442-2042.2009.02431.x. PMID 20377835.
- ↑ Gómez-Ruiz S, Maksimović-Ivanić D, Mijatović S, Kaluđerović GN (2012). "On the discovery, biological effects, and use of Cisplatin and metallocenes in anticancer chemotherapy". Bioinorg Chem Appl. 2012: 140284. doi:10.1155/2012/140284. PMC 3401524. PMID 22844263.